Piramal Enterprises, Dr. Reddy's and TVS Motor Company to see some action today

Dr. Reddys Laboratories Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500124 | NSE: DRREDDY

01 Apr 2021 Evaluate

Piramal Enterprises’ subsidiary company -- Piramal Pharma (PPL) has entered into an agreement to acquire a 100% stake in Hemmo Pharmaceuticals (Hemmo) for an upfront consideration of Rs 775 crore and earn-outs linked to achievement of milestones. Consequent to this Acquisition, Hemmo would become a wholly owned subsidiary of PPL. Hemmo is one of India’s largest manufacturers of synthetic peptides with a legacy of more than thirty eight years in business supplying peptide products and custom peptide synthesis.

Dr. Reddy's Laboratories has entered into a partnership agreement with ABCD Technologies LLP (to be renamed as IndoHealth Services LLP). The transaction is in line with the Company's purpose of accelerating access and affordability of medicines to all, and the strategy of leveraging digital technology and infrastructure towards this.

TVS Motor Company’s two-wheeler exports clocked 100,000 units milestone in March 2021. An increase in motorcycle sales in key markets across the globe has significantly contributed to this achievement. The Company has a presence in over 60 countries in geographies across Africa, South East Asia, Indian Sub-Continent, Central & Latin America and is seeking to enter more markets in Europe and North America as well. The company's key export products include the TVS Apache, TVS HLX series, TVS Stryker series, etc.

Vedanta is planning to set up a coastal copper smelter plant in India for Rs 10,000 crore. The move comes nearly three years after its plant in Tamil Nadu was shut on environmental concerns and at a time when copper prices are on the rise globally.

Mawana Sugars has completed the transfer of its unit Siel Chemical Complex to Bodal Chemicals for a consideration of Rs 137 crore. The company had entered into an agreement on February 9, 2021 for transfer of its chemical unit located in Punjab to Ahmedabad-based Bodal Chemicals. The sale of this unit will ensure long-term financial stability to the company. There would not be any change in the shareholding of company consequent to this sale.

Zuari Agro Chemicals has resumed its production at NPK - B Plant with effective from March 30, 2021. Earlier, the company had temporarily shut down its plant due to delay in the arrival of raw materials.

Central Depository Services (India) (CDSL) has incorporated a wholly owned subsidiary company ‘CDSL IFSC’ on March 30, 2021 having its registered office at GIFT City, Gandhinagar, Gujarat. The company has incorporated a wholly owned subsidiary company to undertake the activities as a depository in GIFT IFSC including that of a Foreign Depository as mandated by the regulators

Dr. Reddys Labs. Share Price

1356.85 -19.45 (-1.41%)

30-Jun-2026 16:59 View Price Chart

Peers

Company Name	CMP
Sun Pharma. Inds.	1862.70
Dr. Reddys Labs.	1356.85
Cipla	1465.15
Zydus Lifesciences	1112.20
Lupin	2420.15
View more..

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.